Thuốc Benlysta
Thuốc Benlysta (Human Genome Sciences and GlaxoSmithKline) thử
nghiệm trị bệnh Lupus
Scheduled for a March 10 approval, Benlysta could be the first new
lupus drug developed in 50 years.
It isn't a cure. Taken monthly, the intravenous drug prevents flare-ups
by inhibiting B-cells found in the immune system, which in lupus patients
attack the body and organs.
Lupus isn't easy to treat, which explains why Benlysta has received
widespread attention and why Human Genome Sciences' stock price has
skyrocketed over the last two years. Regulators have concerns about
Benlysta's long-term effectiveness and the drug's effectiveness on African
Americans. The FDA has delayed approval once already.
Thuốc Ipilimumab (Bristol-Myers Squibb) thử nghiệm trị Ung thư da
melanoma, Ung thư nhiếp hộ tuyến và ung thư phổi
Also referred to by the brand name Yervoy, ipilimumab improves
survival for people with a deadly form of skin cancer by stimulating the
immune system to fight cancer cells.
In a study released in June, 45.6% of advanced melanoma patients
taking ipilimumab after failing to respond to chemotherapy were alive after a
year.
That's a big deal. Available treatments work poorly, and once
melanoma spreads survival averages six to nine months.
The drug's side effects can be severe. Bristol-Myers, meanwhile, is
testing ipilimumab on earlier stages of melanoma, as well as prostate and
lung cancer.
An FDA decision is due by March 26.
Thuốc Telaprevir (Vertex Pharmaceuticals and Johnson & Johnson)
thử nghiệm ngăn ngừa siêu vi trùng viêm gan C phát triển
Big expectations for the hepatitis C drug helped to fuel Vertex's share
price over the last several years. The drug prevents the hepatitis C virus from
reproducing and can eventually eliminate it faster than current therapies.
That's welcome news for the 3.9 million Americans infected with the
virus, which causes liver damage. Current treatments take months and cure
far fewer patients, leaving them to face worsening health problems.
Telaprevir could receive FDA approval in May, along with a similar
drug from Merck & Co.
Thuốc INCB18424 (Incyte and Novartis) thử nghiệm trị bệnh
Myelofibrosis, những bệnh rối loạn máu, bệnh vẩy nến và ung thư
Known simply as INCB18424, Incyte's compound could be the first
treatment approved by the FDA for myelofibrosis, a rare and often fatal
disorder that scars bone marrow so it can't manufacture blood cells.
The drug isn't a cure. It reduces swelling of the spleen and other
symptoms. Meanwhile, it's being tested on other blood disorders, as well as
psoriasis and cancer.
Incyte's application should arrive at the FDA in the next few months.
If the agency fast tracks their review, a decision is possible before year end.
Thuốc Xarelto (Johnson & Johnson and Bayer) thử nghiệm ngăn ngừa
đông máu, ngừa đông máu khi giải phẫu những bệnh xương hay do bệnh
rung tâm nhĩ (Atrial fibrillation)
Also known as rivaroxaban, Xarelto made our list in 2009 and 2010.
But the drug ran into delays at the FDA.
Still, it could be the first in a new class of blood-clot-preventing drugs
to hit the U.S., with approval expected late this year.
Already available in Europe and Canada, Xarelto rivals Coumadin and
its generic, warfarin, which prevent stroke but require frequent blood tests.
Xarelto was initially intended to prevent strokes in patients
undergoing orthopedic surgery, but J&J is also seeking approval for atrial
fibrillation (an irregular heart rhythm).
.. all five drugs hold promise, offering patients … reasons to hope.
Dược sĩ Trịnh Nguyễn Đàm Giang